Issue 49: Nanomedicine business and product news October-November 2017


Nanomedicine company announces clinical trial for nanoparticle cancer therapy

NanOlogy LLC, a clinical-stage pharmaceutical development company, has announced enrollment of the first patient in a Phase 2 clinical trial of intraperitoneally (IP) administered NanoPac®(nanoparticle paclitaxel) sterile suspension in patients with ovarian cancer. Part of a broad nanoparticle technology platformdeveloped by the company, NanoPac will be evaluated for safety and efficacy after IP instillation of NanoPac at the end of cytoreductive (debulking) surgery.

CorNeat Vision Unveils a Revolutionary Artificial Cornea

CorNeat Vision, an Israeli ophthalmic medical devices startup, has completed the design and development stage of its revolutionary cornea implant (CorNeat KPro / Keratoprosthesis), an associated implantation tool and dedicated manufacturing process. Following solution validation in NZW rabbits, the company is currently initiating formal biocompatibility and safety tests toward first implantation in Humans by mid-2018. The CorNeat KPro implant is a patent-pending synthetic cornea that utilizes advanced cell technology to integrate artificial optics within resident ocular tissue. The CorNeat KPro is produced using nanoscale chemical engineering that stimulates cellular growth.

US company to develop nano delivery system based on Spanish research

GB Sciences, Inc. has obtained the exclusive worldwide license to intellectual property covering a time-released cannabinoid formulation from the Universidad de Seville (“USE”), the Universidad de Cadiz (“UCA”), and the Centro de Investigación Biomédica en Red de Salud Mental (“CIBERSAM”). In collaboration with Dr. Juan A. Micó and Dr. Esther Berrocoso (UCA and CIBERSAM), this group of researchers from USE demonstrated that their time-released cannabinoid formulation provided relief from neuropathic pain in rats for eleven days from one orally-administered dose, as recently published in the journal Nanomedicine: Nanotechnology, Biology, and Medicine (

New partnership to develop novel nano immunotherapy

NexImmune and The Leukemia & Lymphoma Society (LLS) have entered a partnership to advance the Company’s novel cellular immunotherapy into Phase 1 clinical testing for patients with high risk AML who have relapsed after an allogeneic hematopoietic stem cell transplant (HSCT).

NexImmune is advancing immunotherapy products based on the Company’s proprietary Artificial Immune Modulatory (AIM) nanotechnology platform.  The AIM technology enables simultaneous enrichment, expansion and activation of cytotoxic T cells directed at multiple tumor-relevant antigen targets (Tumor Associated Antigens or neo-antigens) across a broad range of both solid and hematologic malignancies.

Start-up to treat blood clots with nanotech

Researchers in the Indiana University School of Medicine’s Department of Emergency Medicine have launched a startup to develop nanotechnology to help people affected by blood clots in the lungs, also known as pulmonary embolisms. The technology could improve patient outcomes and reduce risk. Indiana Lysis Technologies is early in the development process of its nanoparticle clot-digesting therapeutic, but it has received positive preliminary results in demonstrating proof of concept.

Genisphere raises $7M  for nanotechnology platform

Genisphere LLC has completed a $7 million capital raise to advance its 3DNA® nanotechnology platform for targeted drug delivery and to serve other corporate purposes. Genisphere completed the raise to support accelerating interest in advancing its 3DNA scaffold into the clinic and enabling follow-on studies and programs currently underway with biotech and pharma partners.

This round of proceeds will expand development of Genisphere’s 3DNA® nanotechnology which allows multivalent combinations of payload and cell-specific targeting molecules in a single therapeutic entity. According to the Company, active targeting guides drug to the disease site to increase efficacy, while degradation and clearance reduce payload toxicity, collectively raising therapeutic index. Genisphere has published preliminary studies describing therapeutic 3DNA®-based candidates for oncology, ophthalmology, neurology and other indications.